Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Morepen LaboratoriesNSE:MOREPENLAB -0.67%76 EV-to-EBIT is 25.18 as of Jul. 17, 2026, which is 18% above its 10-year median of 21.31. GuruFocus rates NSE:MOREPENLAB with a GF Score™ of 76/100 and a GF Value™ of ₹49.98 (Modestly Overvalued). The stock has 9 warning signs investors should review. Among 689 Drug Manufacturers companies, Morepen Laboratories ranks worse than 67.49% on this metric.
The historical rank and industry rank for Morepen Laboratories's EV-to-EBIT or its related term are showing as below:
NSE:MOREPENLAB'
s EV-to-EBIT Range Over the Past 10 Years
Min: 10.09 Med: 21.31 Max: 320.35
Current: 25.18
During the past 13 years, the highest EV-to-EBIT of Morepen Laboratories was 320.35. The lowest was 10.09. And the median was 21.31.
NSE:MOREPENLAB's EV-to-EBIT is ranked worse than 67.49% of 689
companies
in the Drug Manufacturers industry
Industry Median: 15.73
vs NSE:MOREPENLAB: 25.18
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Morepen Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was ₹19,463 Mil.
Morepen Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,363 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories EV-to-EBIT Related Terms
Morepen Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Morepen Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MOREPENLAB vs ZTS, UTHR: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Morepen Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Morepen Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Morepen Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Morepen Laboratories's EV-to-EBIT falls into.
Morepen Laboratories's current Enterprise Value is ₹34,329 Mil.
Morepen Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,363 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Morepen Laboratories (NSE:MOREPENLAB) has a EV-to-EBIT of 25.18 as of Jul. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Morepen Laboratories and its competitors. This is 18% above median its historical median of 21.31. Over the past decade, Morepen Laboratories' EV-to-EBIT has ranged from 10.09 to 320.35. According to the industry distribution chart, Morepen Laboratories ranks #465 out of 689 companies in the Drug Manufacturers industry, placing it in the top 67.5%.
Is Morepen Laboratories' EV-to-EBIT too high?
Morepen Laboratories' current EV-to-EBIT of 25.18 is 18% above median its 10-year median of 21.31. Over the past 10 years, this metric has ranged from a low of 10.09 to a high of 320.35. The Drug Manufacturers industry median EV-to-EBIT is 15.73. Morepen Laboratories' value of 25.18 is 60.1% above this industry median. Based on the distribution chart, Morepen Laboratories ranks #465 out of 689 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Morepen Laboratories has a GF Score™ of 76/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Morepen Laboratories' EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Morepen Laboratories ranks #465 out of 689 companies for EV-to-EBIT. This places Morepen Laboratories in the lower half of its industry. The industry median EV-to-EBIT is 15.73. Morepen Laboratories' value of 25.18 is 60.1% above this benchmark. Historically, Morepen Laboratories' own EV-to-EBIT has ranged from 10.09 to 320.35 over the past decade. While the company's 10-year median is 21.31 vs. the industry median of 15.73, Morepen Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Morepen Laboratories's current EV-to-EBIT of 25.18 is 60.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Morepen Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Morepen Laboratories's current EV-to-EBIT is 25.18, which is 18% above median its own 10-year median of 21.31. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Morepen Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Morepen Laboratories (NSE:MOREPENLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹49.98, compared to a current price of ₹60.83 — trading 21.7% above its estimated fair value. The current EV-to-EBIT is 25.18, which is 18% above median its 10-year median of 21.31 and 60.1% above the Drug Manufacturers industry median of 15.73. Morepen Laboratories' overall GF Score™ is 76/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Morepen Laboratories (NSE:MOREPENLAB), the current EV-to-EBIT is 25.18 as of Jul. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Morepen Laboratories (NSE:MOREPENLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Morepen Laboratories stock appears to be overvalued.
The current stock price of ₹60.83 is trading 21.7% above its estimated GF Value™ of ₹49.98.
GuruFocus considers Morepen Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:MOREPENLAB:
EV-to-EBIT: 25.18 (18% above median its 10-year median of 21.31)
GF Value™: ₹49.98 vs. price of ₹60.83 (21.7% above fair value)
Industry Position: 60.1% above the Drug Manufacturers median (#465 of 689)
No single metric tells the full story. See the NSE:MOREPENLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Morepen Laboratories Ltd is in the business of manufacturing, producing, developing, and marketing various Active Pharmaceutical Ingredients (APIs), branded and generic formulations, and also Home Health products. Some of the products offered by the company include various drug formulations, APIs, digital thermometers, heat belts, pulse oximeters, nutritional tablets, pain sprays, and others. The company operates in a single segment namely, Pharmaceuticals. Geographically, the company derives maximum revenue from India and the rest from the United States of America, and the Rest of the world.
76GF Score
Get the complete analysis for NSE:MOREPENLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MOREPENLAB has been successfully added to your 
